Navigation Links
Watson and Richter Announce Exclusive License Agreement for Esmya™
Date:12/16/2010

strength are expected to contribute to the successful development and marketing of Esmya™ in North America. I am convinced that via the acquisition of PregLem and the commercialisation of Esmya™, we will create increasing value for our investors", said Erik Bogsch, Managing Director of Gedeon Richter Plc.

"Esmya™ has successfully completed clinical trials in Europe, so we have significant clinical knowledge and confidence in the development requirements as we move to late-stage trials in the U.S. and Canada," said Ernest Loumaye, CEO and Co-Founder of PregLem.

Uterine fibroids (myomas) are the most common benign, solid tumors of the female genital tract, affecting between 20 and 25 percent of women of reproductive age.  The condition is characterized by excessive uterine bleeding, anemia, pain, frequent urination or incontinence, and occasional interruption of fertility.  Approximately 300,000 surgical procedures are performed annually to address uterine fibroids, including approximately 230,000 hysterectomies.  GnRH agonists are the only approved treatment for uterine fibroids when associated with anemia but their use has been relatively limited due to side effects resulting from the suppression of estrogen to castration levels (hot flushes, depression, mood swings, loss of libido, vaginitis and loss of bone mineral density).

About Esmya

Ulipristal acetate is a first-in-class, orally active selective progesterone receptor modulator which reversibly blocks the progesterone receptors in target tissues.  PregLem has completed clinical trials in Europe, and is initiating the registration procedure in the EU. PregLem will market Esmya™ in Europe.

About RichterRichter is a leading multinational pharmaceutical company headquartered in Budapest, Hungary. With consolidated sales of approximately EUR 1 billion (US$1.3 billion) in 2009 and a market capitalization of EUR 3.2 billi
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
3. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
4. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
5. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
6. Watson and Barr Settle Lawsuit Over Oxytrol(R)
7. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
8. Watson Completes Acquisition of Eden Biodesign
9. Watson to Present at Credit Suisse Healthcare Conference
10. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
11. Watson Files FDA Application for Generic Rozerem(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)...   , First patient ... efficacy and safety of MSB0010718C in patients with metastatic Merkel ... aggressive skin cancer lacking effective treatments   MSB0010718C is ... clinical trial for the treatment of solid tumors that aims ... a subsidiary of Merck KGaA, Darmstadt, Germany ...
(Date:7/28/2014)... , July 28, 2014  Dignity Health St. ... received the Get With The Guidelines®-Stroke Silver-Plus Quality ... outlined by the American Heart Association/American Stroke Association ... the number four cause of death and a ... the United States , according to the ...
(Date:7/28/2014)... , July 28, 2014 STAAR Surgical ... manufacturer and marketer of implantable lenses and delivery systems ... second quarter results and conference call with investors to ... 30, 2014.  The Company rescheduled the release date and ... funeral services for Hideo Watanabe , President of ...
Breaking Medicine Technology:EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 2EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 3EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 4EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 5Dignity Health St. Mary's Medical Center Honored with Quality Achievement Award for Stroke Care 2Dignity Health St. Mary's Medical Center Honored with Quality Achievement Award for Stroke Care 3STAAR Surgical Moves Second Quarter Earnings Release and Conference Call One Day to July 31 2
... K-V Pharmaceutical Company ( KVa; KVb) (the "Company") ... HOLX ) that site initiation and patient enrollment has ... in the ongoing trial of Gestiva™ (hydroxyprogesterone caproate injection, 250 ... of preterm birth in women pregnant with a single baby ...
... The Wireless-Life Sciences Alliance (WLSA) , which convenes innovators, globally relevant ... in wireless technologies, today hailed its partner organizations for their collaboration and ... , , ... , , ...
Cached Medicine Technology:K-V Pharmaceutical Announces Update on Confirmatory Trial of Gestiva(TM) 2K-V Pharmaceutical Announces Update on Confirmatory Trial of Gestiva(TM) 3K-V Pharmaceutical Announces Update on Confirmatory Trial of Gestiva(TM) 4K-V Pharmaceutical Announces Update on Confirmatory Trial of Gestiva(TM) 5K-V Pharmaceutical Announces Update on Confirmatory Trial of Gestiva(TM) 6K-V Pharmaceutical Announces Update on Confirmatory Trial of Gestiva(TM) 7K-V Pharmaceutical Announces Update on Confirmatory Trial of Gestiva(TM) 8K-V Pharmaceutical Announces Update on Confirmatory Trial of Gestiva(TM) 9Wireless-Life Sciences Alliance (WLSA) Applauds Partner Organizations for Supporting Goal of Improving Healthcare Via Wireless Technologies 2Wireless-Life Sciences Alliance (WLSA) Applauds Partner Organizations for Supporting Goal of Improving Healthcare Via Wireless Technologies 3
(Date:7/29/2014)... July 29, 2014 – Silverado, a provider of memory ... that it is a Bronze winner in the 35th Annual ... Through a Child's Eye and Silverado Resident Visits ... a Child's Eye , seven-year-old Mia Sandoval shares her experience ... a memory care community in Los Angeles. The feel-good video ...
(Date:7/29/2014)... 29, 2014 According to a new ... leading global authority in medical device market research, the ... to over $8 billion by 2018. This growth ... the transcatheter heart valve market, which is comprised of ... transcatheter mitral valve repair (TMVR) segments. , There are ...
(Date:7/29/2014)... 29, 2014 According to the New ... the recreational and the medicinal sectors is mirroring the ... becomes more accepted in mainstream culture, many are turning ... the traditional and more dangerous forms of smoking the ... quite the trend in legalized states such as Colorado ...
(Date:7/29/2014)... 2014Today the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) and ... to improve access to essential pain medications for people ... ACS, Treat the Pain initiative, this new partnership will ... HIV/AIDS services throughout the country. , Swaziland has ... than 26 percent of adults ages 15-49 infected. Many ...
(Date:7/29/2014)... 29, 2014 Officials with OZ Naturals ... in the UK in September. , Craig Romero, CEO of ... Sept. 7 on Amazon.co.uk. , “Demand for OZ Naturals products ... are truly looking forward to serving the European market,” Romero ... bestselling Vitamin C serum and hyaluronic acid ...
Breaking Medicine News(10 mins):Health News:Silverado Selected a Winner in the 35th Annual Telly Awards for Producing Inspiring Online Video Content 2Health News:Global Transcatheter Heart Valve Devices Market Outlook to 2018: Breakthrough Developments led by Abbott, Edwards LifeSciences and Medtronic 2Health News:Global Transcatheter Heart Valve Devices Market Outlook to 2018: Breakthrough Developments led by Abbott, Edwards LifeSciences and Medtronic 3Health News:Marijuana Edibles Sales Show Growth in Market 2Health News:New partnership to improve access to essential pain medications for people living with HIV 2Health News:OZ Naturals to Launch Its Products in the UK 2
... planned strategic growth that ... Lansing and Michigan, LANSING, Mich., Oct. 8 In ... Grand River, accommodate up to 500 new jobs for,Lansing and ... subsidiary Accident Fund Insurance Company of America announced,today it will ...
... MURRYSVILLE, Pa., Oct. 8 Dixtal Medical, Inc.,and ... that Dixtal Medical,has acquired the Novametrix pulse oximetry ... will be marketed under the,Dixtal/Novametrix brand pursuant to ... Novametrix, founded in 1978 and acquired,by Respironics in ...
... mean more estrogen, bringing higher odds for the illness, researchers ... and shape of a woman,s hips may affect her daughter,s ... The study of 6,370 Finnish women found that breast cancer ... mothers with relatively wide hips, and nearly seven times higher ...
... Brothers is proud to be the,leading supplier of Official ... extends over 90 years. The embroidered badges and awards,produced ... substances. As a global manufacturer, Lion Brothers maintains ... substances in any of its,manufacturing processes. Lion tests materials ...
... Bristol-Myers Squibb Company,(NYSE: BMY ) will announce ... 25. During a conference call on October 25 at ... executives will,address inquiries from investors and analysts. Investors ... a live,webcast of the call at http://www.bms.com/ir ...
... or useless, the appendix now appears to have a reason ... bacteria living in the human gut. , Drawing upon a ... postulate that the beneficial bacteria in the appendix that aid ... evacuates the intestines and emerge afterwards to repopulate the gut. ...
Cached Medicine News:Health News:Accident Fund Will Make Board of Water & Light's Ottawa Street Station Power Plant in Lansing Its New National Headquarters 2Health News:Accident Fund Will Make Board of Water & Light's Ottawa Street Station Power Plant in Lansing Its New National Headquarters 3Health News:Dixtal Medical Purchases Novametrix Pulse Oximetry Business from Respironics 2Health News:Dixtal Medical Purchases Novametrix Pulse Oximetry Business from Respironics 3Health News:Woman's Hips Might Indicate Daughter's Breast Cancer Risk 2Health News:Appendix isn't useless at all: It's a safe house for bacteria 2Health News:Appendix isn't useless at all: It's a safe house for bacteria 3
... Drug Interaction Principles is the number one ... , An understanding of drug interactions has ... Since publication of the first edition of ... pharmacopoeia - coupled with prolonged human life ...
... drug information reference that integrates ... patient care guidelines., The sixth ... 4,700 drugs, including the latest ... indications, dosages, side effects and ...
Updated for 2006 with more than 800 complete drug entries, this mobile reference provides instant access to all the drug information nurses need in day-to-day practice....
... ACM-8 loads and unloads two centrifuges with ... via Cap Recognition the tube type is ... batches of three 5 position racks into ... single centrifuge ACM can be offered for ...
Medicine Products: